Corporate Information
January 28, 2025
Lund, January 28, 2025, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has granted Active Biotech’s US patent application 17/939,109 for laquinimod in eye disorders. “We continue our dedicated work with the laquinimod patent portfolio to optimize protection for its use in sight-threatening eye disorders…
December 18, 2024
In accordance with a decision made by the Annual General Meeting held on May 22, 2024, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2024, and the Chairman of the Board. If a shareholder does not exercise its right…
December 9, 2024
Lund, December 9, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on tasquinimod, a small molecule immunomodulator in development for myelofibrosis are now available on the company’s website. The data were presented at the 66th American Society of Hematology Annual Meeting (ASH 2024) in San Diego,…
November 13, 2024
Lund, November 13, 2024, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has issued a Notice of Allowance for Active Biotech’s patent application related to methods of treating eye diseases associated with excessive vascularization using laquinimod. The patent, which was filed under application no. 17/939,109,…
November 5, 2024
Lund, November 5, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that an abstract with preclinical data for tasquinimod in myelofibrosis has been accepted for presentation at the 66th American Society of Hematology Annual Meeting in San Diego, December 7-10, 2024 (ASH 2024). The abstract demonstrating efficacy of tasquinimod…
October 30, 2024
Lund, Sweden, October 30, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the clinical phase I/II study of Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition (HOVON 172 MF) has received full approval from the European Medicines Agency (EMA) and the Institutional Ethics Committees.…
October 23, 2024
The Extraordinary General Meeting of Active Biotech was held on October 23, 2024. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved to amend the Articles of Association, whereby the limits for the company’s share capital are changed to not less than…
October 23, 2024
Lund, October 23 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has granted Active Biotech’s patent application covering a proprietary developed eye drop formulation of laquinimod. The patent “Laquinimod formulation for ocular use”, published on October 23, 2024 under European patent number 4312986,…
September 24, 2024
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Extraordinary General Meeting of shareholders to be held on Wednesday, October 23, 2024 at 11 a.m. CEST in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
September 10, 2024
Lund, September 10 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to the ongoing clinical phase I biodistribution study of laquinimod eye drops in patients undergoing vitrectomy. A proprietary formulation of laquinimod for corneal application was developed, taking the specific physico-chemical characteristics of this agent into account,…
July 15, 2024
Lund, July 15 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to a clinical study of tasquinimod in patients with relapsed refractory multiple myeloma (RRMM) being conducted at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia. The study is ongoing in its expansion cohort…
July 1, 2024
Lund, July 1, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into a clinical study agreement for a Phase II investigator-initiated clinical study investigating the use of tasquinimod in myelofibrosis. The study will be led by Lucia Masarova, M.D., assistant professor of Leukemia at The University…
May 28, 2024
Lund, May 28, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announces today that NeoTX Therapeutics, exclusive licensee of naptumomab estafenatox (naptumomab, NAP) from Active Biotech, will present initial results from phase IIa trial with NAP and docetaxel in advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) patients, at the American Society of…
May 22, 2024
The Annual General Meeting of Active Biotech was held on May 22, 2024. The following main resolutions were passed.In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2023, and that the Company’s accumulated loss shall be carried forward.…
May 22, 2024
Lund, May 22, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces it has entered into an exclusive license agreement with the Wistar Institute of Anatomy and Biology (“Wistar”), Philadelphia, US for the global rights to Wistars interest in the joint IP relating to the use of tasquinimod in combination…
April 23, 2024
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Annual General Meeting of shareholders to be held on Wednesday, May 22, 2024 at 5 p.m. CEST in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
April 3, 2024
Lund, April 3, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the clinical phase I biodistribution study Safety, Tolerability, and Distribution of Laquinimod Eye Drops: The LION Study (clinicaltrials.gov NCT06161415) with laquinimod eye drops is now recruiting patients following the approval from the Food and Drug Administration (FDA)…
December 22, 2023
Lund, December 22, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to the timelines of its scheduled clinical studies to be initiated in 2024, backed by the company’s recently completed successful financing round. The next step in the development of the drug candidate laquinimod will be a…
December 14, 2023
Lund, December 14, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on tasquinimod, a small molecule immunomodulator, in myelofibrosis and myelodysplastic syndrome (MDS) are now available on the company’s website. The data were presented at the 65th American Society of Hematology Annual Meeting (ASH 2023) in…
December 5, 2023
Lund, December 5, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that it has entered into a clinical trial collaboration agreement with the Global Ophthalmic Research Center (GORC), Los Altos, CA, US for a phase I clinical ocular biodistribution study with laquinimod eye drops. GORC is the study administrative…
December 1, 2023
In accordance with a decision made by the Annual General Meeting held on May 24, 2023, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2023, and the Chairman of the Board. If a shareholder does not exercise its right…
December 1, 2023
Lund, December 1, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that a recorded presentation and an interview on the positioning of tasquinimod in the evolving landscape of myelofibrosis with Professor Rebekka Schneider-Kramann are available on the company website (www.activebiotech.com). Active Biotech has communicated earlier that it will focus…
November 2, 2023
Lund, November 2, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that two abstracts with preclinical data for tasquinimod in myelofibrosis and myelodysplastic syndrome have been accepted for presentation at the 65th American Society of Hematology Annual Meeting in San Diego, December 9-12, 2023 (ASH 2023). The abstract demonstrating…
September 13, 2023
Lund, September 13 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that data from the recently completed phase I study with the eye drop formulation of laquinimod, a small molecule immunomodulator in development for non-infectious uveitis, together with results from the intraocular biodistribution study of laquinimod eye drops in rabbit,…
September 11, 2023
Lund Sweden, September 11, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces the successful completion of the dose escalation of tasquinimod in combination with the orally administered antimyeloma agents ixazomib, lenalidomide, and dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma. 6 patients have been treated with increasing…
July 31, 2023
Lund, July 31 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into a clinical trial collaboration agreement with Stichting Haemato-Oncologie Volwassenen Netherland (HOVON) and Stichting Oncode Institute (Oncode) for the upcoming clinical proof-of-concept trial of tasquinimod in myelofibrosis. HOVON will be the legal sponsor of the…
May 30, 2023
Lund, May 30 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that data from the recently completed phase I study with the eye drop formulation of laquinimod, a small molecule immunomodulator in development for ocular inflammation, will be presented in a poster session at the International Ocular Inflammation Society (IOIS)…
May 26, 2023
Lund, May 26 2023 – Active Biotech (NASDAQ Stockholm; ACTI) announces today that tasquinimod, when given as monotherapy or in combination with ixazomib, lenalidomide and dexamethasone (IRd), has a favourable safety profile in heavily pre-treated patients with a median of 8 previous lines. All 15 patients included in this interim…
May 24, 2023
The Annual General Meeting of Active Biotech was held on May 24, 2023. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2022, and that the Company’s accumulated loss shall be carried…
April 27, 2023
Lund, April 27 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that new data from the ongoing study with tasquinimod, a small molecule immunomodulator, in multiple myeloma will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, 2-6 June, 2023.…
April 25, 2023
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Annual General Meeting of shareholders to be held on Wednesday, May 24, 2023 at 5 p.m. CEST in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
April 19, 2023
Lund, April 19 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announces today that NeoTX Therapeutics, exclusive licensee of naptumomab estefanatox (naptumomab, Nap) from Active Biotech presented the following interim results from the phase Ib trial with naptumomab in combination with the checkpoint inhibitor durvalumab in patients with advanced or metastatic…
April 11, 2023
Lund, Sweden — April 11, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced the acceptance of an abstract at the American Association for Cancer Research (AACR) 2023 Annual Meeting in Orlando, Florida, April 14-19, 2023. The poster will present the results of safety and preliminary activity in the phase…
January 30, 2023
Lund, January 30, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced the completion of the phase I clinical study testing the safety and tolerability of the newly developed laquinimod eye drop formulation in healthy subjects. According to the results, the eye drop was safe and well tolerated both at…
December 13, 2022
Lund, December 13, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on tasquinimod, a small molecule immunomodulator, in myelodysplastic syndrome (MDS), are now available on the company’s website. The data were presented at a poster presentation at the 64th American Society of Hematology Annual Meeting in…
December 5, 2022
In accordance with a decision made by the Annual General Meeting held on May 19, 2022, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2022, and the Chairman of the Board. If a shareholder does not exercise its right…
November 3, 2022
Lund, November 3, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that an abstract with preclinical data on tasquinimod, a small molecule immunomodulator, in myelodysplastic syndrome (MDS), has been accepted for presentation at the 64th American Society of Hematology Annual Meeting in New Orleans, Louisiana, December 10-13, 2022 (ASH…
October 24, 2022
Lund, October 24, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has issued a decision to grant Active Biotech’s patent related to use of laquinimod as treatment of eye diseases associated with excessive vascularization. The patent will be issued on 25 October, 2022, under…
June 1, 2022
Lund, June 1, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab estafenatox (NAP, naptumomab), in combination with docetaxel in patients with advanced or metastatic non-small cell lung…
May 19, 2022
The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical attendance. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was…
May 18, 2022
Lund May 18, 2022 – Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. “The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for…
April 26, 2022
Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech’s patent related to use of laquinimod as treatment of eye diseases associated with excessive vascularization. The patent will be granted on May 11, 2022, under…
April 20, 2022
The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Thursday, May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting…
February 9, 2022
FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye disorders. The fourth quarter in particular proved to be a busy period, with continued strong development with all the prioritized projects in our portfolio. Tasquinimod Clinical…
February 9, 2022
Lund, February 9, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in treatment of myelofibrosis (MF).…
February 7, 2022
Lund Sweden, February 7, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been dosed in the combination part of the phase Ib/IIa clinical study of tasquinimod in relapsed or refractory multiple myeloma. In this part of the study treatment with tasquinimod will be tested…
January 4, 2022
Lund, January 4, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that Dr. Erik Vahtola, MD, PhD, has been appointed Chief Medical Officer (CMO), effective January 1, 2022. He will join the executive management team and be responsible for the development of the company´s clinical project portfolio within solid…
December 15, 2021
Lund, December 15, 2021 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on its candidate drug tasquinimod, a small molecule immunomodulator, are now available on the company’s website. The data were presented at two poster presentations at the 63rd ASH Annual Meeting & Exposition in Atlanta, Georgia.…
December 10, 2021
In accordance with a decision made by the Annual General Meeting held on May 19, 2021, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2021, and the Chairman of the Board. If a shareholder does not exercise its right…
December 10, 2021
Lund, December 10, 2021 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first subject has been dosed in the phase I clinical study of the newly developed eye-drop formulation of the company’s candidate drug laquinimod. Laquinimod is being developed as a new treatment for non-infectious non-anterior uveitis and…